SentenceSentimentTitleUrlDate
NEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts PositiveNEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts http://www.reuters.com/news/health/article/us-catalyst-pharms-drugpricing/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000-idUSKCN1Q02862019-02-12
U.S. Senator Bernie Sanders sent a letter to Catalyst last week asking the company to justify its pricing NeutralNEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts http://www.reuters.com/news/health/article/us-catalyst-pharms-drugpricing/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000-idUSKCN1Q02862019-02-12
Floridabased Catalyst which in November received U.S. approval to sell the drug set a list price of a year NegativeNEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts http://www.reuters.com/news/health/article/us-catalyst-pharms-drugpricing/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000-idUSKCN1Q02862019-02-12
But an Express Scripts spokeswoman said the pricing takes advantage of vulnerable patients who need this and called Catalyst an example of a company misusing the Orphan Drug Act NegativeNEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts http://www.reuters.com/news/health/article/us-catalyst-pharms-drugpricing/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000-idUSKCN1Q02862019-02-12
Catalyst CEO Patrick McEnany declined to comment except to say that the company would be responding to Senator Sanders request in a timely manner NegativeNEW YORK Catalyst Pharmaceuticals Inc said on Monday that it expects its drug for a rare disease which had long been available to patients for free will cost more than per year including rebates to insurers and other discounts http://www.reuters.com/news/health/article/us-catalyst-pharms-drugpricing/catalyst-pharma-sees-net-price-of-drug-once-free-topping-300000-idUSKCN1Q02862019-02-12